MarketCap
CRISPR Therapeutics AG CRSP
$ 50.09
3.3%
Facebook
X
Telegram
CRISPR Therapeutics AG ROE Ratio | CRSP
Annual ROE Ratio CRISPR Therapeutics AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.26 | -18.96 | -8.16 | -34.67 | 15.74 | -20.96 | 7.12 | -42.07 | -36.39 | -9.96 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.74 | -42.07 | -17.86 |
Quarterly ROE Ratio CRISPR Therapeutics AG
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.55 | -24.35 | -31.31 | -31.97 | -27.11 | -25.98 | -20.18 | -18.34 | -11.66 | -13.72 | -11.62 | -8.89 | -19.53 | -21.97 | -26.58 | -31.7 | -31.69 | -27.82 | 10.23 | 11.94 | 11.4 | 9.58 | -28.33 | -29.93 | -20.25 | 10.02 | 4.16 | -0.71 | -16.1 | -51.64 | -51.51 | -48.51 | -36.3 | -37.95 | -34.76 | -34.99 | -27.72 | 9.58 | 13.49 | 19.85 | 54.67 | 53.01 | -3.62 | 42.17 | 21.83 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54.67 | -51.64 | -12.45 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
-91.72 | - | -6.97 % | $ 657 M |  USA |
 |
Capricor Therapeutics
CAPR
|
-34.35 | $ 8.97 | 4.3 % | $ 417 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 28.5 | 3.04 % | $ 1.33 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
7.32 | - | 1.68 % | $ 4.65 B |  China |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 3.6 | -1.64 % | $ 385 M | USA |
 |
Jaguar Health
JAGX
|
0.29 | $ 0.4 | -2.16 % | $ 933 K | USA |
 |
Arvinas
ARVN
|
-18.67 | $ 6.41 | -2.14 % | $ 454 M | USA |
 |
Cerus Corporation
CERS
|
-24.33 | $ 2.03 | -4.93 % | $ 387 M | USA |
 |
Beam Therapeutics
BEAM
|
-6.46 | $ 26.43 | 2.15 % | $ 2.61 B | USA |
 |
Fortress Biotech
FBIO
|
74.19 | $ 1.86 | 0.82 % | $ 51.9 M | USA |
 |
Inhibrx
INBX
|
-554.81 | $ 84.71 | 5.52 % | $ 3.99 B | USA |
 |
Entera Bio Ltd.
ENTX
|
-87.31 | $ 3.16 | 5.69 % | $ 146 M |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
682.51 | - | - | $ 459 M | USA |
 |
Legend Biotech Corporation
LEGN
|
-29.62 | $ 23.43 | 3.95 % | $ 8.64 B | USA |
 |
CytomX Therapeutics
CTMX
|
-17.54 | $ 2.19 | 2.1 % | $ 302 M | USA |
 |
Krystal Biotech
KRYS
|
16.8 | $ 300.7 | 0.15 % | $ 8.7 B | USA |
 |
Kura Oncology
KURA
|
-160.03 | $ 7.15 | 5.15 % | $ 627 M | USA |
 |
Inhibikase Therapeutics
IKT
|
-27.91 | $ 1.5 | 4.17 % | $ 147 M | USA |
 |
Heron Therapeutics
HRTX
|
-139.54 | $ 0.29 | 2.25 % | $ 48.3 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-352.75 | $ 1.22 | -16.21 % | $ 57.2 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-25.0 | $ 10.56 | 8.5 % | $ 834 M | USA |
 |
Aytu BioScience
AYTU
|
-40.4 | $ 1.82 | 0.55 % | $ 22.4 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
-22.56 | - | -5.76 % | $ 99.8 M | USA |
 |
Innoviva
INVA
|
23.12 | $ 19.09 | -0.78 % | $ 1.29 B | USA |
 |
BioCardia
BCDA
|
-919.33 | $ 0.86 | -3.12 % | $ 5.73 M | USA |
 |
Kindred Biosciences, Inc.
KIN
|
-32.3 | - | 0.11 % | $ 419 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-28.65 | $ 2.44 | 9.91 % | $ 15.6 B |  Australia |
 |
Shineco, Inc.
TYHT
|
-10.15 | - | -3.90 % | $ 97.2 M | China |
 |
Millendo Therapeutics, Inc.
MLND
|
-110.13 | - | -5.36 % | $ 20.2 M | USA |
 |
Certara
CERT
|
-0.15 | $ 12.12 | -0.53 % | $ 1.94 B | USA |
 |
Dyadic International
DYAI
|
-597.58 | $ 0.33 | -2.68 % | $ 11.9 M | USA |
 |
Intec Pharma Ltd
NTEC
|
-97.21 | - | -12.45 % | $ 17.7 M | Israel |
 |
Oramed Pharmaceuticals
ORMP
|
32.07 | $ 3.86 | -0.77 % | $ 160 M | Israel |
 |
Anika Therapeutics
ANIK
|
-7.58 | $ 14.56 | -24.68 % | $ 209 M | USA |
 |
Aprea Therapeutics
APRE
|
-101.27 | $ 0.53 | 6.6 % | $ 3.47 M | USA |
 |
Galectin Therapeutics
GALT
|
24.11 | $ 3.13 | 4.86 % | $ 200 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
15.38 | $ 72.79 | 1.62 % | $ 7.56 B | USA |
 |
Progenity, Inc.
PROG
|
179.94 | - | -3.47 % | $ 164 M | USA |
 |
Genprex
GNPX
|
-203.83 | $ 2.09 | -0.48 % | $ 1.95 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
-68.71 | - | 1.52 % | $ 136 M | USA |
 |
Innate Pharma S.A.
IPHA
|
226.58 | $ 1.43 | 2.14 % | $ 128 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
-166.53 | - | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 56.03 | -0.16 % | $ 10.7 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
-214.18 | $ 1.15 | -0.86 % | $ 6.3 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
-126.53 | $ 10.99 | 9.03 % | $ 234 K | USA |
 |
Milestone Pharmaceuticals
MIST
|
-0.15 | $ 0.76 | 9.73 % | $ 80.7 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
10.4 | $ 93.79 | 6.17 % | $ 6.96 B | USA |
 |
Lipocine
LPCN
|
-66.52 | $ 1.58 | 3.27 % | $ 8.61 M | USA |
 |
Seres Therapeutics
MCRB
|
12.88 | $ 1.97 | -5.74 % | $ 17.5 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
-47.83 | $ 399.41 | -0.17 % | $ 8.96 B | USA |